Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study
A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a signi...
Gespeichert in:
Veröffentlicht in: | West Kazakhstan medical journal 2024-12, Vol.66 (4), p.453-459 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a significant reduction in body temperature, decrease in CRP, and an increase in the levels of blood cells. Revealed clinical improvement was seen in 69.7% of cases, 8.5% of patients showed deterioration in their condition and were transferred to the ICU, 13.6% died. Olokizumab was well tolerated except for slight elevation in live enzymes, such as aspartate transaminase and alanine transaminase. |
---|---|
ISSN: | 2707-6180 2707-6199 |
DOI: | 10.18502/wkmj.v66i4.17780 |